Genefluidics is a cutting-edge brand that offers innovative products and services in molecular-based diagnostics. Their mission is to revolutionize the field of healthcare by providing rapid and accurate solutions to identify pathogens and determine their antimicrobial susceptibility. With their advanced technology, Genefluidics enables healthcare professionals to obtain crucial information in a fraction of the time compared to traditional methods.

Genefluidics' portfolio includes the HAI ID AST Platform, which allows for the identification of hospital-acquired infections in a remarkably fast timeframe of 3-6 hours. By detecting pathogens directly from patient whole blood samples, there is no longer a need to wait days for positive blood cultures. This not only saves time but also improves patient outcomes by enabling evidence-based antibiotic use in a timely manner.

Additionally, Genefluidics offers molecular-based pathogen identification (ID) and antimicrobial susceptibility testing (AST) services. These PCR-less tests identify species-specific genes and phenotypic markers of resistance and susceptibility. They provide comprehensive and reliable results without the requirement of a clinical isolate or positive blood sample.

By employing Genefluidics' solutions, healthcare professionals can make informed treatment decisions and ensure the most effective and targeted care for their patients. Genefluidics is at the forefront of diagnostic technology, contributing to saving time, money, and most importantly, lives